Zobrazeno 1 - 10
of 715
pro vyhledávání: '"nirmatrelvir/ritonavir"'
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 5011-5015 (2024)
Masafumi Seki, Chie Kubosawa, Makoto Ono, Fumitaka Kamoshita, Atsuko Shimizu, Kotaro Mitsutake Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, JapanCorrespondence: Masafumi
Externí odkaz:
https://doaj.org/article/9c577554de274623a6ebe79d098ed4b9
Autor:
Fatemeh Saheb Sharif-Askari, Hawra Ali Hussain Alsayed, Narjes Saheb Sharif-Askari, Ali Al Sayed Hussain, Saleh Al-Muhsen, Rabih Halwani
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain. This retrospective cohort study assessed
Externí odkaz:
https://doaj.org/article/72d8815603524462895e7943dff8ad85
Autor:
Huaiya Xie, Yaqi Wang, Yan Xu, Luo Wang, Junping Fan, Siqi Pan, Chuan Shi, Xiaoyan Liu, Xiaoxing Gao, Xiaobei Guo, Siyuan Yu, Jia Liu, Dongming Zhang, Yanli Yang, Hong Zhang, Jinglan Wang, Aohua Wu, Xueqi Liu, Jihai Liu, Huadong Zhu, Xiang Zhou, Xinlun Tian, Mengzhao Wang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 pat
Externí odkaz:
https://doaj.org/article/d88b3e55da7d4fe7873f45189db8222e
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 3967-3978 (2024)
Ximiao Yu,1,* Ruiqi Luo,2,* Guijuan Xie,2 Jiali Ji,3,4 Jiehong Wang,1 Xiyue Li,3 Xiaojun Qian,2 Xun Wang1,2,5 1Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu Province, People’s Republic of China; 2Department of Pulmonary and Cr
Externí odkaz:
https://doaj.org/article/d8e82d493dc54688b5b23018834f80fe
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Nirmatrelvir/ritonavir (NM/r) is a safe and effective oral antiviral therapeutic used for treatment of mild-to-moderate COVID-19. Case reports described a clinical rebound syndrome whereby individuals experience a relapse of sympt
Externí odkaz:
https://doaj.org/article/8ec47f4ce96142e3bac78c2e69e6d596
Autor:
Takeshi Tomida, Takeshi Kimura, Kazuhiro Yamamoto, Atsushi Uda, Yuki Matsumoto, Naoki Tamura, Masashi Iida, Akiko Tanifuji, Kumiko Matsumoto, Naomi Mizuta, Kei Ebisawa, Goh Ohji, Tomohiro Omura, Kentaro Iwata, Ikuko Yano
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract Purpose While nirmatrelvir/ritonavir (NMV-r) has been positioned as a first-line treatment for mild to moderate COVID-19, it has multiple and significant drug-drug interactions (DDIs). The use of NMV-r in Japan has been limited compared to t
Externí odkaz:
https://doaj.org/article/96e1fb92be494ee0a05d38ad27641599
Autor:
Abby E. Rudolph, Farid L. Khan, Tanya G. Singh, Srinivas Rao Valluri, Laura A. Puzniak, John M. McLaughlin
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 9, Pp 2035-2052 (2024)
Abstract Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small
Externí odkaz:
https://doaj.org/article/e054eaf1567e4fc8aa96a7d8270415d7
Autor:
Ee Vien Low, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatmen
Externí odkaz:
https://doaj.org/article/bee5dbb338f14b44a6e178ea6248f6a9
Autor:
Hanako Naganawa, Yoshiki Katada, Shunsaku Nakagawa, Keisuke Umemura, Hiroki Ishimura, Moto Kajiwara, Hiroki Endo, Mitsuhiro Sugimoto, Yurie Katsube, Kinuka Kotani, Saki Ohta, Daiki Hira, Masahiro Tsuda, Yuki Kita, Takashi Kobayashi, Tomohiro Terada
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Background Among the oral antivirals used for treating patients with mild-to-moderate novel coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (NMV/RTV) and ensitrelvir (ESV) are inhibitors of cytochrome P450 (CYP) 3A, and therefore
Externí odkaz:
https://doaj.org/article/a725f98f1f0545a89762afa6a3dc25bc
Autor:
Myriam Drysdale, Holly Tibble, Vishal Patel, Daniel C. Gibbons, Emily J. Lloyd, William Kerr, Calum Macdonald, Helen J. Birch, Aziz Sheikh
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving
Externí odkaz:
https://doaj.org/article/e6f97d2fec77487f82c4dc9b302868dd